Chronic administration of LNA‐miR‐29 reduces aortic aneurysm formation in angiotensin II and Marfan syndrome models via upregulation of several ECM genes (Merk et al, 2012) providing in vivo evidence supporting the promise of miR‐29 antagonism reducing the extent of vascular diseases. This evidence concerns the gene AGT and aortic aneurysm.